.png){kind=icon}
.png){kind=icon}
Return
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
.png){kind=icon}
PRE
AI
M
A
H
S
E
O
S
M
T
G
J
S
M
J
M
H
Á
L
J
C
V
R
L
A
E
N
E
S
S
G
E
X
L
W
O
Z
Y
I
Z
A
E
E
D
S
D
G
S
R
M
DOI：10.1158/1538-7445.SABCS23-GS01-03.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Journal
IF:
16.6
Papers:
10.9W
Citations:
11.9W
Organization
No organization information available
Cited Papers